000163032 001__ 163032
000163032 005__ 20240229123146.0
000163032 0247_ $$2pmid$$apmid:32893501
000163032 0247_ $$2altmetric$$aaltmetric:89657103
000163032 0247_ $$2doi$$a doi: 10.1002/cam4.3413
000163032 0247_ $$2doi$$adoi: 10.1002/cam4.3413
000163032 037__ $$aDKFZ-2020-01823
000163032 041__ $$aeng
000163032 082__ $$a610
000163032 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000163032 245__ $$aPrevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities.
000163032 260__ $$aHoboken, NJ$$bWiley$$c2020
000163032 3367_ $$2DRIVER$$aarticle
000163032 3367_ $$2DataCite$$aOutput Types/Journal article
000163032 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667893735_5814
000163032 3367_ $$2BibTeX$$aARTICLE
000163032 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163032 3367_ $$00$$2EndNote$$aJournal Article
000163032 500__ $$a#EA:C110#LA:C110# 2020 Nov;9(21):8053-8061
000163032 520__ $$aFatigue prevalence and severity have been assessed in a variety of studies, yet, not in a standardized way, and predominantly in breast cancer patients. Systematic, comparative investigations across a broad range of cancer entities are lacking.The FiX study systematically enrolled 2244 cancer patients across 15 entities approximately 2 years after diagnosis. Fatigue was assessed with the multidimensional EORTC QLQ-FA12 questionnaire. Physical, emotional, cognitive, and total fatigue were compared across entities and with normative values of the general population. Differences in patients' characteristics and cancer therapy between entities were taken into account using analyses of covariance models.Across all entities, mean physical fatigue levels were significantly higher than age- and sex-matched means of the general population for all cancer entities (all Bonferroni-Holm adjusted P < .01). For most entities also emotional and cognitive fatigue levels were significantly higher than normative values. Age- and sex-standardized physical fatigue prevalence ranged from 31.8% among prostate to 51.7% among liver cancer patients. Differences between entities could not be fully explained by sex, age, BMI, or cancer therapy. Adjusted for these factors, mean physical fatigue was higher for stomach (P = .0004), lung (P = .034), kidney (P = .0011), pancreas (P = .081), and endometrium (P = .022) compared to breast cancer patients. Adjusted means of emotional fatigue were also lowest in breast cancer patients and significantly higher in stomach (P = .0047), bladder (P = .0036), and rectal (P = .0020) cancer patients.Physical, emotional, and cognitive fatigue is prevalent in all 15 investigated cancer entities even 2 years after diagnosis. Fatigue in breast cancer patients, the so-far most studied group, is in the lowest range among all entities, suggesting that the extent of fatigue is still insufficiently determined. Entity-specific problems might need to be considered in the treatment of fatigue.
000163032 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000163032 588__ $$aDataset connected to PubMed,
000163032 7001_ $$0P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aHermann, Silke$$b1$$udkfz
000163032 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b2$$udkfz
000163032 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b3$$eLast author$$udkfz
000163032 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.3413$$n21$$p8053-8061$$tCancer medicine$$v9$$x2045-7634$$y2020
000163032 909CO $$ooai:inrepo02.dkfz.de:163032$$pVDB
000163032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000163032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163032 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163032 9141_ $$y2020
000163032 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2018$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-01-09
000163032 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-09
000163032 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-09
000163032 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000163032 9201_ $$0I:(DE-He78)M110-20160331$$kM110$$lM110 Epidemiologisches Krebsregister Baden-Württemberg$$x1
000163032 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x2
000163032 980__ $$ajournal
000163032 980__ $$aVDB
000163032 980__ $$aI:(DE-He78)C110-20160331
000163032 980__ $$aI:(DE-He78)M110-20160331
000163032 980__ $$aI:(DE-He78)C071-20160331
000163032 980__ $$aUNRESTRICTED